COAGULATION AND ANTICOAGULATION PARAMETERS IN MULTIPLE SCLEROSIS PATIENTS WITH AND WITHOUT COVID-19 DOI Creative Commons
Tetiana Halenova, Nataliia Raksha,

Tetiana B. Vovk

et al.

Clinical and Preventive Medicine, Journal Year: 2024, Volume and Issue: 3, P. 36 - 45

Published: May 8, 2024

The aim. To investigate plasma levels of main coagulation and fibrinolytic factors in MS patients with without COVID-19 history. Materials methods. A total 127 participants were enrolled this study, including 97 30 healthy controls (HC). Patients divided into two groups: MS+Covid group (n=41) – MS, who had a laboratory-verified diagnosis the past 3-6-month period (n=56) did not suffer from previously. Determination prothrombin, plasminogen, tissue-type plasminogen activator (tPA), inhibitor-1 (PAI-1), protein C (PC), soluble thrombomodulin (TM) was performed by means enzyme-linked immunosorbent assay. Spectrophotometric techniques used to determine concentrations fibrinogen, fibrin monomeric complexes (SFMC) as well activity inhibitory potential α-2-antiplasmin. Results. characterized elevated D-dimer, SFMC, TM compared HC, while PC concentration differ between HC groups. Plasma level plasmin significantly decreased group. tPA reduced PAI-I increased HC. an α-2-antiplasmin note, most studied parameters groups, except C, activity. Conclusions. results our study showed that have got altered hemostasis parameters; however, further is necessary find out relationship particular components systems pathophysiology MS. Additionally, findings demonstrated SARS-CoV-2 infection limited effect on patients, causing changes only few parameters,

Language: Английский

COAGULATION AND ANTICOAGULATION PARAMETERS IN MULTIPLE SCLEROSIS PATIENTS WITH AND WITHOUT COVID-19 DOI Creative Commons
Tetiana Halenova, Nataliia Raksha,

Tetiana B. Vovk

et al.

Clinical and Preventive Medicine, Journal Year: 2024, Volume and Issue: 3, P. 36 - 45

Published: May 8, 2024

The aim. To investigate plasma levels of main coagulation and fibrinolytic factors in MS patients with without COVID-19 history. Materials methods. A total 127 participants were enrolled this study, including 97 30 healthy controls (HC). Patients divided into two groups: MS+Covid group (n=41) – MS, who had a laboratory-verified diagnosis the past 3-6-month period (n=56) did not suffer from previously. Determination prothrombin, plasminogen, tissue-type plasminogen activator (tPA), inhibitor-1 (PAI-1), protein C (PC), soluble thrombomodulin (TM) was performed by means enzyme-linked immunosorbent assay. Spectrophotometric techniques used to determine concentrations fibrinogen, fibrin monomeric complexes (SFMC) as well activity inhibitory potential α-2-antiplasmin. Results. characterized elevated D-dimer, SFMC, TM compared HC, while PC concentration differ between HC groups. Plasma level plasmin significantly decreased group. tPA reduced PAI-I increased HC. an α-2-antiplasmin note, most studied parameters groups, except C, activity. Conclusions. results our study showed that have got altered hemostasis parameters; however, further is necessary find out relationship particular components systems pathophysiology MS. Additionally, findings demonstrated SARS-CoV-2 infection limited effect on patients, causing changes only few parameters,

Language: Английский

Citations

0